Full Title: A Phase I/II, Multicentre, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib In Paediatric and Young Adult Patients With Previously Treated Solid Tumours/A Phase I/II Study of Cobimetinib in Children and Young Adults with Previously Treated Solid Tumours
Sarcoma Type: Non alveolar Rhabdomyosarcoma
Age: Phase 1 6 to less than 18 - phase 2 6 to less than 30
Phase: Phases 1 and 2
If you have rhabdomyosarcoma that has not responded to previous treatment or that has returned, you may be treated with chemotherapy. Cobimentinib is a type of drug called a tyronsine kinase inhibitor (TKI). TKIs work by blocking the signals in the cancer cells that tell them to grow. This trial is trying to find out whether the TKI cobimetinib is a safe an effective drug to treat children and young adults with soft tissue sarcoma.